Fully underwritten Retail Entitlement Offer to open at 9:00 am ( Melbourne time) on 19 June 2024 Retail Entitlement Offer to raise approximately A$55.0m ( US$36.9m 1 ) will close at 5:00 pm ( Melbourne time) on 10 July 2024 Prospectus and personalized application forms to be dispatched to eligible
Fully underwritten Retail Entitlement Offer to raise a further approximately A$55.9m ( US$36.9m 1 ) will open on 19 June 2024 and close at 5:00 pm ( Melbourne time) on 10 July 2024 MELBOURNE, Australia and PRINCETON, N.J. , June 13, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT,
Financing extends Opthea’s cash runway through Phase 3 topline data readout for both pivotal trials of sozinibercept in wet AMD Phase 3 topline data readout accelerated for COAST to early Q2 calendar year 2025, and anticipated for ShORe in mid-calendar year 2025 MELBOURNE, Australia and PRINCETON,
MELBOURNE, Australia and PRINCETON, N.J. , June 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular
Phase 3 program enrolled 1,984 patients across COAST and ShORe trials Trials designed to replicate superiority in visual outcomes demonstrated in Phase 2b Topline data from both pivotal trials expected in mid-CY2025 MELBOURNE, Australia and PRINCETON, N.J.
MELBOURNE, Australia and PRINCETON, N.J. , May 01, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular
MELBOURNE, Australia and PRINCETON, N.J. , April 25, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular
Brings extensive experience in retinal and ophthalmology diseases MELBOURNE, Australia and PRINCETON, N.J. , April 08, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent
MELBOURNE, Australia and PRINCETON, N.J. , April 04, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage biopharmaceutical company developing novel therapies to treat highly prevalent and progressive retinal diseases, including wet age-related macular
Former CymaBay Therapeutics CEO brings extensive leadership experience to his role as a Non-Executive Director and Audit and Risk Committee Chair MELBOURNE, Australia and PRINCETON, N.J. , April 03, 2024 (GLOBE NEWSWIRE) -- Opthea Limited (ASX/NASDAQ: OPT “Opthea”, the “Company”), a clinical-stage